Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Revenue (2019 - 2025)

BridgeBio Pharma's Revenue history spans 7 years, with the latest figure at $154.2 million for Q4 2025.

  • For Q4 2025, Revenue rose 2521.18% year-over-year to $154.2 million; the TTM value through Dec 2025 reached $502.1 million, up 126.26%, while the annual FY2025 figure was $502.1 million, 126.26% up from the prior year.
  • Revenue for Q4 2025 was $154.2 million at BridgeBio Pharma, up from $120.7 million in the prior quarter.
  • Across five years, Revenue topped out at $211.1 million in Q1 2024 and bottomed at -$830000.0 in Q4 2021.
  • The 5-year median for Revenue is $2.5 million (2021), against an average of $41.1 million.
  • The largest annual shift saw Revenue crashed 780.33% in 2021 before it soared 11461.88% in 2024.
  • A 5-year view of Revenue shows it stood at -$830000.0 in 2021, then surged by 325.3% to $1.9 million in 2022, then fell by 6.68% to $1.7 million in 2023, then surged by 237.08% to $5.9 million in 2024, then surged by 2521.18% to $154.2 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Revenue are $154.2 million (Q4 2025), $120.7 million (Q3 2025), and $110.6 million (Q2 2025).